This research work focused to evaluate the therapeutic efficiency of the drug impregnated into polylactide-coglycolide- PLGA nano sized particles for the management of Ovarian malignancy. The nanosized formulation was lucratively developed by Double Emulsion Solvent Evaporation technique. The formulation optimization was done using CCRD-RSM and characterized in terms of stability studies, sterility studies, in-vitro cytotoxicit y effects, in-vivo anti-cancer activity and therapeutic possessions. The nanosized particles caused an increase in the cyto-toxicity effects of Cisplatin against Ovarian cell adeno carcinoma cells (A2786) (2.3-fold) when compared to the standard Cisplatin. The Nano formulation also made an increase in the therapeutic effects of Cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen when compared to the standard Cisplatin receiver mice. The IC50 worth of Cisplatin and C-PLGA intensifies on ovarian disease cells was 38.53 μg/ml and 24.6 μg/ml which is ~20 fold better compared to the parent compound Cisplatin. Our improved plan of C-PLGA compound was viewed as more deadly on A2780 malignant growth cells. Overall Cisplatinloaded PLGA nanosized particles can be called as a absolute drug candidate for the management of cancer due toits potency to reducethe side effects of cisplatin andits toxicity and therapeuticeffects on Cancer-bearing Albino mice.